
 
 
 
 
 
 
 
 
  34 Claims 
 
 1. A protein which has a molecular weight selected from the group consisting of: 16, 25, 37, 42, 44, 55, 60, 85, 98, 125, 145, 225, and 250 kDa; and which has one or more of the following characteristics: (a) said protein elicits antibodies which bind to the surface of merozoites; (b) said protein elecits an anti-Babesia immunόlogic response against surface-exposed regions of merozoites; and (c) said protein has merozoite-surface-exposed region(s) that can be labeled with a surface-specific labeling procedure. 
 
 
 2. A Babesia merozoite surface protein having a molecular weight selected from the group consisting of 16, 25, 37, 42, 44, 55, 60, 85, 98, 125, 145, 225, and 250 kDa. 
 
 
 3. The 42 kDa protein, according to claim 2, wherein said protein is a glycosylated integral membrane protein. 
 
 
 4. A protein which has the amino acid sequence shown in Figure 1, or an amino acid sequence which is substantially the same, or a fragment of the sequence shown in Figure 1, so long as said substantially same sequence or said fragment retains the biological activity of the sequence shown in Figure 1. 
 
 
 5. The protein, according to claim 4, which has the amino acid sequence shown in Figure 1. 
 
 
 6. A Babesia bovis protein with species- and isolate-common epitopes capable of eliciting immunologic responses in cattle, said protein having a molecular weight selected from the group consisting of 19, 53, 59, and 120 kDa.  
 
 
  35 7. Monoclonal antibodies specific to a Babesia surface protein, where said Babesia surface protein has a molecular weight selected from the group consisting of: 16, 37, 42, 44, 60, 85, 145, and 225 kDa. 
 
 
 8. A monoclonal antibody selected from the group consisting of 23.8.34.24, BABB75, MBOC79, 23.53.156, 23.38.120.8, 23.70.174.83, BABB35A 4 , 23.3.16, 23.10.36, BABB93A J , BABB90C 4 , and 23.28.57.108. 
 
 
 9. A monoclonal antibody reagent useful in determining the presence of pathogens, said reagent containing at least one monoclonal antibody species specific to Babesia. 
 
 
 10. A Babesia DNA fragment that expresses a protein that reacts with an antibody selected from the group consisting of: 23.8.34.24, BABB75, MBOC79, 23.53.156, 23.38.120.8, 23.70.174.83, BABB35A 4 , 23.3.16, 23.10.36, BABB93A l5  BABB90C 4 , and 23.28.57.108. 
 
 
 11. A Babesia DNA fragment which is selected from the group consisting of lambda-Bo6, lambda-Bo25, lambda-Bo44-15, lambda-Bo44-16, Iambda-Bo220-1, and lambda-Bo220-2. 
 
 
 12. A DNA fragment comprising a 1.25 kb insert obtained by the digestion of lambda-Bo44-15 or lambda-Bo44-16 with EcoRI. 
 
 
 13. The DNA sequence shown in Figure 1, or a DNA sequence which is substantially the same, or a fragment of the sequence shown in Figure 1. 
 
 
 14. The DNA sequence shown in Figure 2, or a DNA sequence which is substantially the same, or a fragment of the sequence shown in Figure 2.  
 
 
  36 15. The DNA sequence shown in Figure 3, or a DNA sequence which is substantially the same, or a fragment of the sequence shown in Figure 3. 
 
 
 16. A DNA sequence which codes for a polypeptide where said polypeptide has the the amino acid sequence shown in Figure 1. 
 
 
 17. A DNA sequence which codes for a polypeptide having the amino acid sequence shown in Figure 2. 
 
 
 18. A DNA sequence coding for the polypeptide shown in Figure 4. 
 
 
 19. A DNA sequence selected from the group consisting of PQRPAETQQTQDSAAPSTPAAPSP and PQRPAETQQTQDSTAPGTPAAPSP, and immunological equivalents thereof. 
 
 
 20. A recombinant microorganism transformed with lambda-Bo6, lambda- Bo25, Iambda-Bo220-1; lambda-Bo220-2; lambda-Bo44-15; lambda-Bo44-16; a 1.25 kb insert obtained by the digestion of lambda-Bo44-15 or lambda-Bo44-16 with EcoRI; or a DNA sequence which is the same, substantially the same, or a fragment of one of the sequences shown in Figure 1, Figure 2, or Figure 3. 
 
 
 21. A recombinant microorganism, according to claim 20, wherein said microorganism is an Escherichia coli or Salmonella spp. 
 
 
 22. A recombinant protein produced by a microorganism transformed with lambda-Bo44-15; lambda-Bo44-16; a 1.25 kb insert obtained by the digestion of lambda-Bo44-15 or lambda-Bo44-16 with EcoRI: or a DNA sequence which is the same, substantially the same, or a fragment of, one of the sequences shown in Figure 1, Figure 2, or Figure 3.  
 
 
  37 23. The recombinant protein, according to claim 22, wherein said recombinant protein has the amino acid sequence shown in Figure 1, Figure 2, or Figure 4, or an amino acid sequence which is substantially the same, or a fragment of one of those sequences. 
 
 
 24. A recombinant protein, according to claim 22, wherein said recombinant protein elicits an antibody response to babesiosis in calves immunized with said recombinant protein. 
 
 
 25. The use of a Babesia bovis protein having a molecular weight selected from the group consisting of 16, 25, 37, 42, 44, 55, 60, 85, 98, 125, 145, 225, and 250 kDa, or an immunologic equivalent of said protein, to elicit neutralizing antibodies. 
 
 
 26. A vaccine for conferring immunity to babesiosis on a susceptible animal host, said vaccine comprising an immunizing amount of bacterial cells, or products of bacterial cells, where said cells have been transformed with DNA fragments from Babesia that encode a surface protein. 
 
 
 27. A vaccine, according to claim 26, wherein said bacterial cells have been transformedwithlambda-Bo220-l; lambda-Bo220-2; lambda-Bo44-15; lambda-Bo44- 16; a 1.25 kb insert obtained by the digestion of lambda-Bo44-15 or lambda-B-44-16 with EcoRI: or a DNA sequence which is the same, substantially the same, or a fragment of one of the sequences shown in Figure 1, Figure 2, or Figure 3. 
 
 
 28. A vaccine, according to claim 26, wherein said bacterial cells, or products of bacterial cells, are in combination with an appropriate pharmaceutical carrier. 
 
 
 29. A vaccine comprising a protein, or mixture of proteins, where said proteins are Babesia proteins, or immunologic equivalents thereof, where said  38 Babesia proteins have a molecular weight selected from the group consisting of 16, 25, 37, 42, 44, 55, 60, 85, 98, 125, 145, 225, and 250 kDa. 
 
 
 30. The vaccine, according to claim 29, wherein the protein, or at least one of the proteins, has one of the amino acid sequences shown in Figure 1, Figure 2, or Figure 4, or an amino acid sequence which is substantially the same, or a fragment of one of those sequences. 
 
 
 31. A method for vaccinating a susceptible animal host to confer immunity to babesiosis, said method comprising administering an immunizing amount of bacterial cells, or products of bacterial cells, where said cells have been transformed with DNA fragments from Babesia that encode a surface protein. 
 
 
 32. A method, according to claim 31, wherein said bacterial cells have been transformedwithlambda-Bo220-l;Iambda-Bo220-2; lambda-Bo44-15; lambda-Bo44- 16; a 1.25 kb insert obtained by the digestion of lambda-Bo44-15 or lambda-B-44-16 with EcoRI: or a DNA sequence which is the same, substantially the same, or a fragment of one of the sequences shown in Figure 1, Figure 2, or Figure 3. 
 
 
 33. A method, according to claim 31, wherein said bacterial cells, or products of bacterial cells, are in combination with an appropriate pharmaceutical carrier. 
 
 
 34. A method for detecting the presence of anti-Babesia antibodies in a clinical sample of material suspected of containing these antibodies, said method comprising the performance of a whole cell or cell lysate ELISA on the said clinical sample, said ELISA is performed using recombinant microorganisms which express Babesia specific antigens.  
 
 
  39 35. A method for detecting the presence of anti-Babesia antibodies in a clinical sample suspected of containing these antibodies, said method comprising (a) contacting the sample with whole cell or cell lysate recombinant microorganisms which express Babesia specific antigens, said contacting done under conditions which will promote specific antigen/antibody immunocomplex formation between antigens expressed by the microorganism and antibodies present in the sample; and (b) detecting immunocomplex formation by means of a label to thereby detect the presence of Babesia antibodies in the sample. 
 
 
 36. A method of determining the presence of Babesia in a biological fluid, said method comprising the steps of (a) providing an aliquot of the biological fluid to be studied; (b) contacting said aliquot with a measured amount of antibodies species specific to Babesia antigens; and (c) determining whether any reaction with said antibodies occurs. 
 
 
 37. A method, according to claim 36, wherein the antibodies have a predetermined fluorescence response to a given optical stimulation. 
 
 
 38. A method, according to claim 36, wherein the amount of reaction is determined and the presence of Babesia antigens is quantitatively derived therefrom. 
 
 
 39. A method for the detection of evidence of babesiosis in bovine or tick samples comprising tissue or fluid, said method comprising contacting said sample with a DNA probe where said probe comprises labeled single-stranded DNA whose sequence is sufficiently homologous with the DNA of Babesia so that the DNA of the probe specifically binds with the DNA of said Babesia.   
 
 
 40 40. A method for detecting evidence of Babesia bovis and/or Babesia bigemina in a bovine or tick sample comprising tissue or fluid, said method comprising contacting said sample with a DNA probe where said probe comprises the DNA fragment known as lambda-Bo6, or an equivalent thereof. 
 
 
 41. A method of detecting evidence of Babesia bovis in a bovine or tick sample comprising tissue or fluid, said method comprising contacting said sample with a DNA probe where said probe comprises the DNA fragment lambda-Bo25, or an equivalent thereof. 
 
 
 42. A plasmid selected from the group consisting of pBoό and pBo25. 
 
 
 43. A method, according to claim 39, wherein said probe is labeled by means of radioactive, fluorescent, bioluminescent, or chemiluminescent entities. 
 
 
 44. A method, according to claim 39, wherein said probe is labeled by biotin. 
 
 
 45. A probe for the detection of babesiosis, said probe comprising labeled single-stranded DNA whose sequence is sufficiently homologous with the DNA of Babesia so that the probe specifically binds with DNA of said Babesia. 
 
 
 46. A probe, according to claim 45, wherein said DNA comprises a Babesia DNA which is the same, substantially the same, or a fragment of one of the DNA sequences shown in Figure 1, Figure 2, or Figure 3. 
 
 
 47. A probe, according to claim 45, wherein said DNA comprises an insert selected from the group consisting of lambda-Bo6, lambda-Bo25, lambda-Bo44-15, lambda-Bo44-16, Iambda-Bo220-1, and lambda-Bo220-2.  
 
 
 
 
 
 
 
 
 
 
